Oura's Revenue Just Jumped 74% — and Its IPO Filing Shows It's Not Just a Wearables Company Anymore

Oura’s IPO filings suggest fast, profitable growth: revenue of slightly over $1.2B for the nine months ending June 30 (+74% YoY) and net income rising from about $1.5M to nearly $60.8M. Subscription/membership growth is accelerating, with membership revenue up 122% YoY despite hardware still representing 80% of revenue; gross margin on member revenue is reported at 89%. The company plans to leverage AI on 42B hours of biometric data to generate health predictions and recommendations, with the WSJ valuing the deal at over $11B.

Analysis

The real market signal here is not the IPO itself; it is that biometric hardware is being re-priced as a recurring-data platform. If investors accept that the subscription layer can carry SaaS-like multiples, the beneficiaries are the adjacent names with similar narratives but cleaner public-market disclosure, especially AAPL and DXCM, while pure hardware wearables are at risk of being forced into lower-margin bundles and promotions to defend share.

The first 30-60 days are mostly about float mechanics and valuation anchoring, not fundamentals. A profitable growth story can still trade poorly if insiders are locked and the public float is small, because early scarcity can exaggerate the move and then reverse once supply normalizes. The bigger 6-18 month question is whether this is a durable habit-forming product or a consumer gadget with a high renewal rate while the novelty lasts; that distinction drives whether the market assigns software-like EV/revenue or simply a consumer-device multiple.

Contrarian view: the consensus is probably underestimating churn and overestimating the defensibility of the sensor moat. The moat is the longitudinal dataset, but that only monetizes if management can convert wellness engagement into higher-ARPU services without hitting privacy/regulatory friction or raising CAC too fast. The key falsifiers are a weak first post-IPO quarter on paid-member retention, slower membership ARPU expansion, or any sign the market is paying for a TAM story before it has proven reproducible unit economics.

Key Decisions for Investors

• Do not chase the IPO print; wait 4-6 weeks post-listing and for float/lockup details before putting capital at risk. If the stock holds above the offer range after the first earnings-related reset, the risk/reward improves materially.
• Initiate a relative-value long DXCM / short GRMN basket if the market starts capitalizing Oura as a subscription-health platform. DXCM has the cleaner recurring-revenue model; GRMN is more exposed if wearable multiples compress back toward hardware norms.
• Use any post-IPO enthusiasm to fade pure hardware wearables, not the platform story. A short in GRMN or a put-spread structure over 3-6 months offers better asymmetry than chasing the IPO upside.
• Watch AAPL as the stealth winner: if consumer demand for biometrics and health coaching is validated, Apple can bundle similar features into an installed base without separate hardware economics. This is a medium-term, not day-one, catalyst.
• Set a hard alert on the first reported cohort metrics after listing: paid-member retention, ARPU, and gross margin mix. If membership growth slows or churn rises, treat the valuation as unsupported and step aside.